Zheng Cheng, Song Lanlan, Yu Chang, Zhu Lingye, Zhang Jing, Wang Ning, Liu Mengchu, Li Shini, Wang Liangxing, Shen Zhifa, Huang Xiaoying
Division of Pulmonary Medicine, The First Affiliated Hospital of Wenzhou Medical University, Key Laboratory of Interdiscipline and Translational Medicine, Wenzhou, 325000, China.
Key Laboratory of Laboratory Medicine, Ministry of Education of China, and Zhejiang Provincial Key Laboratory of Medical Genetics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, 325035, China.
Sci China Life Sci. 2025 Feb;68(2):454-466. doi: 10.1007/s11427-023-2556-4. Epub 2024 Nov 26.
Chemotherapy is regarded as a widely used and effective treatment strategy for lung cancer, although most conventional chemotherapeutics cause severe toxic side-effects due to their indiscriminate attacks on both cancerous and normal cells. Although nucleic acid nanomaterials are emerging as a promising drug delivery strategy, their clinical applications are limited by rapid degradation by nucleases and difficulties in targeting cancer cells. In this study, we have developed a Rhein-loaded aptamer-based DNA nanotube (DNT-S6@Rhein) for the targeted and efficient therapy of non-small cell lung cancer. Through the palindrome segments, two specified oligonucleotides were hybridized and folded into the well-defined nanotubes (DNT-S6), with the S6 aptamer distributed outside. The obtained nanotubes exhibited excellent serum stability and targeting ability towards A549 cells due to the firm structure and decoration of the S6 aptamer. Rhein, as an antitumor drug and DNA intercalator, can be effectively inserted into the DNT-S6. The drug-loaded nanotubes rapidly disassembled in intracellular environment and then the released Rhein was found to activate cellular apoptotic process and significantly suppress proliferation, migration and invasion of A549 cells. Moreover, DNT-S6@Rhein could efficiently accumulate in tumor regions, offering compelling therapeutic efficacy and biocompatibility under both in vitro and in vivo settings. These findings of this study provide a promising strategy for mitigating the inevitable systemic side-effects of chemotherapy and expand the potential application of DNA nanostructure on targeted drug delivery.
化疗被视为一种广泛应用且有效的肺癌治疗策略,尽管大多数传统化疗药物会因其对癌细胞和正常细胞的 indiscriminate attacks 而导致严重的毒副作用。尽管核酸纳米材料正成为一种有前景的药物递送策略,但其临床应用受到核酸酶快速降解以及靶向癌细胞的困难的限制。在本研究中,我们开发了一种基于适配体的载有大黄酸的 DNA 纳米管(DNT-S6@Rhein)用于非小细胞肺癌的靶向高效治疗。通过回文片段,两条特定的寡核苷酸杂交并折叠成定义明确的纳米管(DNT-S6),S6 适配体分布在外部。由于其坚固的结构和 S6 适配体的修饰,所获得的纳米管表现出优异的血清稳定性和对 A549 细胞的靶向能力。大黄酸作为一种抗肿瘤药物和 DNA 嵌入剂,可以有效地插入到 DNT-S6 中。载药纳米管在细胞内环境中迅速分解,然后发现释放的大黄酸激活细胞凋亡过程并显著抑制 A549 细胞的增殖、迁移和侵袭。此外,DNT-S6@Rhein 可以有效地在肿瘤区域积累,在体外和体内环境下都具有令人信服的治疗效果和生物相容性。本研究的这些发现为减轻化疗不可避免的全身副作用提供了一种有前景的策略,并扩展了 DNA 纳米结构在靶向药物递送方面的潜在应用。